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Chemotherapy at the
wheel of ALL relapse
Julie Morscio and Pieter Van Vlierberghe | Ghent University
In this issue of Blood, Li et al1 present an extensive in-depth genetic char-
acterization of diagnostic, relapse, and remission samples from a cohort of
103 pediatric patients with acute lymphoblastic leukemia (ALL) treated
according to the Shanghai Children’s Medical Center ALL-2005 frontline
protocol. Together with data obtained from 208 serial bone marrow samples
collected during ALL therapy, their work suggests that relapse in a fraction of
childhood ALL patients is driven by chemotherapy-induced mutations, which
impact therapy response.
Since the early days of cancer treatment
with chemotherapy in the 1960s, the cure
rate of childhood ALL has dramatically
improved.2 Indeed, overall survival rates
for pediatric ALL patients are currently
well above 90% with contemporary treat-
ment protocols that use minimal residual
disease (MRD) measurements to guide
treatment intensity.2 Nevertheless, disease
relapse is still a major clinical problem, and
the biology of relapsed disease as well as
the molecular mechanisms that drive ther-
apy resistance remain poorly understood.2
By means of whole-genome sequencing,
Li et al identified a set of 12 mutations
that were significantly enriched or ex-
clusively present at relapse in a large and
uniformly treated cohort of pediatric ALL.
Of note, this patient population only in-
cluded 16 diagnosis-remission-relapse trios
from T-cell ALL (T-ALL) patients, with a bias
toward tumor material obtained from
TAL1, TAL2, LMO2, or LMO3 rearranged
T-ALLs. Therefore, some of the results
obtained in this study might not be
readily transferable toward all genetic
subtypes of T-ALL.3
Most of the relapse-associated genetic
defects found in this work have previously
been identified in relapsed ALL (TP53,
NR3C1,NR3C2,CREBBP,WHSC1,NT5C2,
PRPS1, PRPS2,MSH2,MSH6, and PMS2)4,5
and are thought to affect chemother-
apy responses to key components of ALL
therapy, such as steroids or thiopurines.6
However, in this study, Li et al also dis-
covered that mutations and focal dele-
tions in the folate metabolism gene
FPGS exclusively occur in relapsed ALL and
cause increased resistance to methotrexate,
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a core component of ALL consolidation
therapy.
Interestingly, very early relapses (,9
months after diagnosis) harbored few of
the relapse-specific mutations mentioned
above, suggesting that they probably
originate from a clone that already existed
at diagnosis (see figure). This preexisting
resistance model for very early ALL relapse
was further supported by doubling time
calculations based on serial MRD samples
that were available from 19 B-cell ALL
patient samples and publicly available
datasets.5 Interestingly, these very early
relapses mainly occurred in ALL cases
harboring mixed-lineage leukemia or BCR-
ABL rearrangements, aberrations noto-
riously associated with poor response to
chemotherapy.2,7
In contrast to very early relapses, relapse-
specificmutationswere significantly enriched
in cases arising later than 9 months after
diagnosis, thereby pointing to potential
on-treatment acquired resistance in a per-
sisting clone (see figure). Indeed, direct
involvement of the uncovered mutations
to response to drugs used for ALL treat-
ment (NR3C1/2, CREBBP, and WHSC1 for
glucocorticoids; NT5C2, MSH2/6, PMS2,
and PRPS1/2 for thiopurines; and FPGS for
methotrexate) suggests that ALL disease
progression can be directly affected by
chemotherapy-induced mutations.
Although usually only a fraction of mu-
tations occurring in cancer is considered
as drivers and actionable therapeutic
targets, the identification of the complete
genetic landscape by whole-genome se-
quencing approaches can provide in-
sights into the mutational processes that
shape cancer genomes and serve as bio-
markers as well as targets for therapeutic
intervention.8 So far, 30 mutational cancer
signatures (ie, unique combinations of
mutations in primary cancers) have been
identified and categorized in the COSMIC
database. For about one-half of these
mutational fingerprints, possible under-
lying molecular mechanisms have been
suggested, for example, increased ac-
tivity of APOBEC enzymes. This family of
cytidine deaminases generates protein
diversity by means of messenger RNA
editing and plays a crucial role in B-cell
receptor somatic hypermutation. Two of
the 9 known mutational signatures iden-
tified in the ALL samples involved APOBEC
and were detected at both diagnosis and
relapse. Notably, the identification of such
signatures can be therapeutically rele-
vant, as exemplified by the APOBEC sig-
nature that can predict response toward
checkpoint blockade immune therapy
in non–small cell lung cancer.9 There-
fore, relapsed ALL cases harboring the
APOBEC signature might also be eligible
for immune therapy.
Interestingly, 2 novel mutational signa-
tures were uniquely detected in the
dominant clone of.25% of ALL relapsed
samples in this study, indicating that they
were acquired early during the course of
the treatment. Of note, in vitro exposure
experiments, using the nontumorigenic
epithelial cell line MCF10A, identified
thioguanines as the causative agents of
one of these signatures, which was re-
sponsible for at least a subset of the
relapse-specific mutations mentioned
above. Although the exact mechanisms
by which thiopurines cause this muta-
tional signature remain unknown, these
findings have major clinical implications
because they indicate that a fraction of
ALL relapses could potentially be pre-
vented in the future by adapting frontline
ALL treatment strategies.
Altogether, the relapse-specific muta-
tions as well as the mutational signatures
reported in this study provide a causative
explanation for a subset of ALL relapses
and pave the way toward the identifica-
tion of biomarkers that could identify
therapy resistance early on during ther-
apy or treatment follow-up. In addition,
as.50% of relapsed ALL samples harbor
at least 1 mutation potentially affecting
therapy response, the mutational resis-
tance profile of each refractory ALL patient
should be taken into account to person-
ally adapt the treatment schedule at re-
lapse. Finally, in a subset of relapsed ALL
samples, the genetic aberrations found
in the tumor cells are not the clear culprits
of resistance, suggesting that also other,
potentially nongenetic factors, could me-
diate certain aspects of therapy resistance.10
Therefore, both genetic and nongenetic
mechanisms of therapy resistance should
eventually be taken into account to clinically
manage relapsed ALL.
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